<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02309970</url>
  </required_header>
  <id_info>
    <org_study_id>GR 05 - 14</org_study_id>
    <nct_id>NCT02309970</nct_id>
  </id_info>
  <brief_title>Perfusion Computer Tomography: Imaging and Clinical Validation Following Reperfusion Therapy in Acute Ischaemic Stroke</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CT perfusion (CTP) of the brain is an innovative technique to identify rapidly regions which
      are only partially or insufficiently perfused during an acute ischemic event. The
      differentiation between the core infarct and the still viable penumbra is its major clinical
      application. CTP helps directly in the decision-making process in the event of acute ischemic
      stroke by increasing the potential of success in patient who can benefit from
      thrombolytic/endovascular treatment.

      The use of CTP in patient selection for thrombolytic/endovascular treatment was never
      evaluated in a prospective randomized study. Yet, clinical experience well demonstrated a
      good correlation between the size of the penumbra and the clinical outcome when done in early
      as well as late stages of the event.

      The importance of identifying the penumbra in the acute phase of the ischemic stroke is
      widely accepted. But crucial evidence to support the predictive value of CTP to predict the
      clinical and anatomical/structural outcomes in the late phases (90 days after) is lacking.

      Currently, the use of CTP is based on theoretical assumptions and expert opinions but a
      randomized prospective study to validate its use is lacking.

      The current guidelines restrict the use of CTP trials and to patients that can't performed
      MRI scan.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The predictive value of CTP in identifying penumbra (salvagable brain tissue) in event of ischemic stroke</measure>
    <time_frame>three month</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Conservative</arm_group_label>
    <description>patient will get treatment with Antiplatelets or Anticoagulant depending on their clinical status/etiology</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV tPA</arm_group_label>
    <description>patient will receive intravenous thrombolysis treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endovascular treatment</arm_group_label>
    <description>patient who will receive endovascular treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acetylsalicylic acid, clopidogrel bisulfate and/or warfarin, Apixaban, Rivaroxaban, Dabigatran</intervention_name>
    <description>subject in this group will receive oral treatment with anti platelet drug</description>
    <arm_group_label>Conservative</arm_group_label>
    <other_name>Aspirin, Plavix, Coumadin, Eliquis,Xarelto, Pradaxa, Sintrom</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alteplase</intervention_name>
    <description>subject in this group will receive intravenous tPA</description>
    <arm_group_label>IV tPA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>endovascular</intervention_name>
    <arm_group_label>Endovascular treatment</arm_group_label>
    <other_name>subject in this group will undergo mechanical thrombectomy</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        men and women admittedto the emergency room at Rabin Medical Center, Beilinson Campus and
        hospitalized at the neurology department.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  NIHSS&gt;=8

          -  up to 6 hours from event onset

        Exclusion Criteria:

          -  mRS&gt;= 3 before the start of the event

          -  life expectency &lt;1 year because other disability disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guy Raphaeli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rabin Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guy Raphaeli, MD</last_name>
    <phone>972-50-4065626</phone>
    <email>guyre@clalit.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ophir Keret, MD</last_name>
    <phone>972-3-9377080</phone>
    <email>ophirke@clalit.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petach Tiqva</city>
        <state>Hamerkaz</state>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guy Raphaeli, MD</last_name>
      <phone>972-50-4065626</phone>
      <email>guyre@clalit.org.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Bivard A, Spratt N, Levi C, Parsons M. Perfusion computer tomography: imaging and clinical validation in acute ischaemic stroke. Brain. 2011 Nov;134(Pt 11):3408-16. doi: 10.1093/brain/awr257.</citation>
    <PMID>22075524</PMID>
  </reference>
  <results_reference>
    <citation>Koton S, Bornstein NM, Green MS. Population group differences in trends in stroke mortality in Israel. Stroke. 2001 Sep;32(9):1984-8.</citation>
    <PMID>11546885</PMID>
  </results_reference>
  <results_reference>
    <citation>National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995 Dec 14;333(24):1581-7.</citation>
    <PMID>7477192</PMID>
  </results_reference>
  <results_reference>
    <citation>Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008 Sep 25;359(13):1317-29. doi: 10.1056/NEJMoa0804656.</citation>
    <PMID>18815396</PMID>
  </results_reference>
  <results_reference>
    <citation>Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, Silver F, Rivera F. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA. 1999 Dec 1;282(21):2003-11.</citation>
    <PMID>10591382</PMID>
  </results_reference>
  <results_reference>
    <citation>Wardlaw JM, Zoppo G, Yamaguchi T, Berge E. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 2003;(3):CD000213. Review. Update in: Cochrane Database Syst Rev. 2009;(4):CD000213.</citation>
    <PMID>12917889</PMID>
  </results_reference>
  <results_reference>
    <citation>Parsons M, Spratt N, Bivard A, Campbell B, Chung K, Miteff F, O'Brien B, Bladin C, McElduff P, Allen C, Bateman G, Donnan G, Davis S, Levi C. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med. 2012 Mar 22;366(12):1099-107. doi: 10.1056/NEJMoa1109842.</citation>
    <PMID>22435369</PMID>
  </results_reference>
  <results_reference>
    <citation>Parsons MW. Perfusion CT: is it clinically useful? Int J Stroke. 2008 Feb;3(1):41-50. doi: 10.1111/j.1747-4949.2008.00175.x. Review.</citation>
    <PMID>18705914</PMID>
  </results_reference>
  <results_reference>
    <citation>Goyal M, Menon BK, Derdeyn CP. Perfusion imaging in acute ischemic stroke: let us improve the science before changing clinical practice. Radiology. 2013 Jan;266(1):16-21. doi: 10.1148/radiol.12112134.</citation>
    <PMID>23264523</PMID>
  </results_reference>
  <results_reference>
    <citation>González RG, Copen WA, Schaefer PW, Lev MH, Pomerantz SR, Rapalino O, Chen JW, Hunter GJ, Romero JM, Buchbinder BR, Larvie M, Hirsch JA, Gupta R. The Massachusetts General Hospital acute stroke imaging algorithm: an experience and evidence based approach. J Neurointerv Surg. 2013 May;5 Suppl 1:i7-12. doi: 10.1136/neurintsurg-2013-010715. Epub 2013 Mar 14. Review.</citation>
    <PMID>23493340</PMID>
  </results_reference>
  <results_reference>
    <citation>Abstracts of the 17th European Stroke Conference. Nice, France. May 13-16, 2008. Cerebrovasc Dis. 2008;25 Suppl 2:1-204. doi: 10.1159/000132086.</citation>
    <PMID>22015331</PMID>
  </results_reference>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2014</study_first_submitted>
  <study_first_submitted_qc>December 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2014</study_first_posted>
  <last_update_submitted>December 4, 2014</last_update_submitted>
  <last_update_submitted_qc>December 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rabin Medical Center</investigator_affiliation>
    <investigator_full_name>Guy Raphaeli</investigator_full_name>
    <investigator_title>Dr. Guy Raphaeli</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Apixaban</mesh_term>
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

